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STATE-OF-THE-ART PAPER STATE-OF-THE-ART PAPERHot Topics in Tetralogy of Fallot 2155
Juan Villafañe, Jeffrey A. Feinstein, Kathy J. Jenkins, Robert N. Vincent, Edward P. Walsh,
Anne M. Dubin, Tal Geva, Jeffrey A. Towbin, Meryl S. Cohen, Charles Fraser, Joseph Dearani,
David Rosenthal, Beth Kaufman, Thomas P. Graham, Jr, on behalf of the Adult Congenital and
Pediatric Cardiology Section, American College of Cardiology
Tetralogy of Fallot (TOF) is the most common cyanotic congenital heart defect. In this
state-of-the-art paper, Villafañe and colleagues review the latest developments in the ﬁeld
of TOF with the aim of improving the long-term management of patients with repaired
TOF. Topics reviewed include imaging, arrhythmias, and the risk of sudden death in
these patients.CLINICAL RESEARCH INVASIVE CARDIOLOGYAscorbic Acid for the Prevention of Contrast-Induced Acute Kidney Injury 2167
Umar Sadat, Ammara Usman, Jonathan H. Gillard, Jonathan R. Boyle
Sadat and colleagues performed a meta-analysis of randomized clinical trials (RCTs)
comparing the use of ascorbic acid with placebo or other treatment options in patients with
contrast-induced acute kidney injury (CI-AKI) undergoing coronary angiography. Nine
RCTs reported data on the incidence of CI-AKI in 1,536 patients. Patients receiving
ascorbic acid had 33% less risk of CI-AKI compared with patients receiving placebo or
alternate pharmacological treatment. The authors conclude that ascorbic acid provides
effective nephroprotection against CI-AKI and may form a part of prophylactic
pharmacological regimen.
Editorial Comment: Peter A. McCullogh, Krittapoom Akrawinthawong, p. 2176(continued on page A-28)
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Gregory S. Thomas, William C. Cromwell, Shariq Ali, Wai Chin, JoAnn D. Flaim, Michael Davidson
Mipomersen is an antisense oligonucleotide that decreases apolipoprotein B synthesis by
inhibitingmessenger ribonucleic acid translation.This study reports on the safety and efﬁcacy of
mipomersen for reducing atherogenic lipids/lipoproteins in hypercholesterolemia in patients in
whom LDL is not controlled with existing therapies. A total of 158 patients with baseline
low-density lipoprotein cholesterol (LDL-C) 100 mg/dl and with, or at high risk for,
coronary heart disease (CHD) were randomized. A total of 60 mipomersen and 44 placebo
patients, with mean baseline LDL-C of 122.7 and 122.6 mg/dl, respectively, completed
treatment. Mipomersen signiﬁcantly reduced LDL-C by 36.9% (placebo: 4.5%),
apolipoprotein B by 38%, and lipoprotein (a) [Lp(a)] by 24%.Common adverse events included
injection site reactions (78% mipomersen, 31% placebo) and ﬂu-like symptoms (34%
mipomersen, 21% placebo). Thomas and colleagues conclude that mipomersen signiﬁcantly
reduced LDL-C, apolipoprotein B, and Lp(a) in hypercholesterolemic patients with, or at risk
for, CHD not controlled by existing therapies.
Editorial Comment: Richard V. Milani, Carl J. Lavie, p. 2185HEART FAILUREMajor Bleeding During Heartmate II Support 2188
Matthew C. Bunte, Eugene H. Blackstone, Lucy Thuita, Jeff Fowler, Lee Joseph, Aska Ozaki,
Randall C. Starling, Nicholas G. Smedira, Maria M. Mountis
Bleeding complications are the most common post-operative adverse events following
Heartmate II (HM II) (Thoratec Corporation, Pleasanton, California) left ventricular assist
device implantation. This study aims to characterize the major bleeding complications during
HM II support. Results show that 139 recipients received 145 devices (from October 2004 to
June 2010) as a bridge to transplant or as destination therapy for advanced heart failure.
The cumulative occurrence of major bleeding was 58% during 171 patient-years of follow-up.
Incidence of major bleeds was 1.14 events/patient-year, with 44% occurring as repeat
bleeding events. The greatest risk for bleeding was noted within 2 weeks post-implant, and
bleeding early after surgery was associated with reduced survival while on HM II support.
Bunte and colleagues conclude that bleeding risks peak early after HM II implantation.
Bleeding from thoracic and gastrointestinal sources dominate these events, although many
patients are transfused for anemia without an apparent source of hemolysis or bleeding.
Editorial Comment: James O. Mudd, Jill M. Gelow, p. 2197(continued on page A-32)
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Vanessa Roldán, Francisco Marín, Sergio Manzano-Fernández, Pilar Gallego,
Juan Antonio Vílchez, Mariano Valdés, Vicente Vicente, Gregory Y. H. Lip
Roldán and colleagues tested the hypothesis that a speciﬁc bleeding risk score, HAS-BLED
(hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile
international normalized ratio, elderly, drugs/alcohol concomitantly), was better at predicting
major bleeding compared with CHADS2 (congestive heart failure, hypertension, 75 years of
age or older, diabetes mellitus, and previous stroke or transient ischemic attack) and
CHA2DS2-VASc (congestive heart failure, hypertension, 75 years of age and older, diabetes
mellitus, previous stroke or transient ischemic attack, vascular disease, 65 to 74 years of age,
female) in anticoagulated atrial ﬁbrillation (AF) patients. A total of 1,370 consecutive AF
patients (49% male, median age 76 years) on warfarin were evaluated. After a median
follow-up of 996 (802 to 1,254) days, 114 patients (30%/year) presented with a major
bleeding event. Of these, 31 were intracranial hemorrhage (0.81%/year). Analysis revealed
that the HAS-BLED score was more accurately associated with major bleeding compared
with CHADS2 and CHA2DS2-VASc scores. The authors conclude that in AF patients, a
validated speciﬁc bleeding risk score, HAS-BLED, should be used for assessing the risk of
major bleeding.CARDIAC IMAGINGLate Gadolinium Enhancement in AF 2205Tomas G. Neilan, Ravi V. Shah, Siddique A. Abbasi, Hoshang Farhad, John D. Groarke,
John A. Dodson, Otavio Coelho-Filho, Ciaran J. McMullan, Bobak Heydari, Gregory F. Michaud,
Roy M. John, Rob van der Geest, Michael L. Steigner, Ron Blankstein, Michael Jerosch-Herold,
Raymond Y. Kwong
There are limited data on the presence, pattern, and prognostic signiﬁcance of left ventricular
(LV) myocardial ﬁbrosis in patients with atrial ﬁbrillation (AF). This study aimed to identify
the frequency, pattern, and prognostic signiﬁcance of LV late gadolinium enhancement
(LGE) in patients with AF. A total of 664 patients without known prior myocardial
infarction, referred for radiofrequency ablation of AF, also underwent cardiac magnetic
resonance imaging. Overall, 73% were male, with an average age of 56 years and an ejection
fraction of 55  10%. LV LGE was found in 88 patients. In the best overall multivariable
model for mortality, age and the extent of LGE were independent predictors of mortality.
The mortality rate was 8.1%/patient-year in patients with LGE versus 2.3%/patient-year in
patients without LGE. Each 1% increase in LGE was associated with a 15% increase in risk
of death. Neilan and colleagues conclude that in patients with AF, LV LGE is a frequent
ﬁnding and a powerful predictor of mortality.
Editorial Comment: Zhiyu Ling, Harikrishna Tandri, p. 2215(continued on page A-33)
DECEMBER 10, 2013 (continued) A-33ENDOCARDITISTrends in Infective Endocarditis Among Older Adults 2217Behnood Bikdeli, Yun Wang, Nancy Kim, Mayur M. Desai, Vincent Quagliarello,
Harlan M. Krumholz
Bikdeli and colleagues sought to determine the hospitalization rates and outcomes of
endocarditis among older adults. Medicare beneﬁciaries 65 years of age with a principal or
secondary diagnosis of endocarditis were evaluated. Results before and after 2007, when
revised guidelines for endocarditis prophylaxis were published, were also analyzed.
Overall, 262,658 beneﬁciaries were hospitalized with endocarditis. The adjusted
hospitalization rate increased from 1999 to 2005, reaching 83.5 per 100,000 person-years
in 2005, and declined during 2006 to 2007. After 2007, the decline continued, reaching
70.6 per 100,000 person-years in 2010. Adjusted 30-day and 1-year mortality ranged from
14.2% to 16.5% and from 32.6% to 36.2%, respectively. There was no consistent change in
adjusted rates of mortality after 2007. This study highlights the high burden of endocarditis
among older adults. There was no observed increase in adjusted rates of hospitalization or
mortality after publication of the 2007 endocarditis prophylaxis guidelines.CONGENITAL HEART DISEASEPulmonary Valve Replacement in Repaired TOF 2227
Paulo Ernando Ferraz Cavalcanti, Michel Pompeu Barros Oliveira Sá, Cecília Andrade Santos,
Isaac Melo Esmeraldo, Rodrigo Renda de Escobar, Alexandre Motta de Menezes,
Orlando Morais de Azevedo, Jr, Frederico Pires de Vasconcelos Silva, Ricardo Felipe de Albuquerque Lins,
Ricardo Carvalho Lima
The outcome of patients with repaired tetralogy of Fallot (rTOF) who have subsequently also
undergone pulmonary valve replacement (PVR) for pulmonic valve insufﬁciency has been
unclear. Cavalcanti and colleagues conducted this review and meta-analysis to better
understand the outcomes of patients with rTOF, with at least moderate pulmonic valve
insufﬁciency, and that have undergone PVR. Results of this meta-analysis reveal that
post-PVR: 1) right ventricular volume and function improve; 2) left ventricular function
improves; 3) QRS duration decreases; and 4) symptoms improve. Based on these results,
the authors conclude that patients with rTOF, with at least moderate pulmonic valve
insufﬁciency that are selected to undergo PVR beneﬁt from the surgery.(continued on page A-34)
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Michelle Gurvitz, Ariane Marelli, Rita Mangione-Smith, Kathy Jenkins
This paper reports on a project to develop quality indicators (QIs) for outpatient management
of adult congenital heart disease (ACHD) patients. Working groups of ACHD experts
reviewed the published literature to identify candidate QIs for 6 ACHD conditions. A total
of 62 QIs, regarding appropriateness and timing of clinical management, testing, and test
interpretation were initially identiﬁed. Eventually, 55 QIs were selected. Final QIs included:
8 for atrial septal defect; 9 for aortic coarctation; 12 for Eisenmenger; 9 for Fontan; 9 for
D-transposition of the great arteries; and 8 for tetralogy of Fallot. Gurvitz and colleagues
have developed the ﬁrst set of QIs for ACHD care. This should facilitate measuring and
improving quality of care for these patients.
